Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.97 USD
Change Today +0.06 / 2.06%
Volume 250.4K
AMPE On Other Exchanges
As of 8:04 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

ampio pharmaceuticals inc (AMPE) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/18/15 - $9.01
52 Week Low
05/20/15 - $1.94
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ampio pharmaceuticals inc (AMPE) Related Businessweek News

No Related Businessweek News Found

ampio pharmaceuticals inc (AMPE) Details

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and decreasing vascular permeability. Its lead product candidates in development include Ampion, which is in Phase III clinical trial for osteoarthritis of the knee; and Optina that is in Phase IIb clinical trial for diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.

23 Employees
Last Reported Date: 02/24/15

ampio pharmaceuticals inc (AMPE) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $455.0K
Chief Financial Officer, Corporate Secretary ...
Total Annual Compensation: $143.5K
Chief Regulatory Affairs Officer
Total Annual Compensation: $255.0K
Chief Scientific Officer and Director
Total Annual Compensation: $305.0K
Compensation as of Fiscal Year 2014.

ampio pharmaceuticals inc (AMPE) Key Developments

Ampio Receives Special Protocol Assessment (SPA) from the FDA and Commences Second Phase III Pivotal Trial of Ampion™

Ampio Pharmaceuticals, Inc. announced it has commenced the second Phase III Study of Ampion to treat pain and inflammation due to osteoarthritis (OA) of the knee. A Special Protocol Assessment (SPA) is a written agreement between the FDA and the sponsor company (Ampio Pharmaceuticals), which defines the clinical trial end points required for approval and significantly reduces the risk of bringing a drug to market.

Ampio Pharmaceuticals, Inc. - Shareholder/Analyst Call

To discuss updates on its pipeline products, AmpionTM and OptinaTM

Goldberg Law PC Announces Securities Class Action Lawsuit Against Ampio Pharmaceuticals, Inc

Goldberg Law PC announced that a class action lawsuit has been filed in the United States District Court for the Central District of California against Ampio Pharmaceuticals, Inc., for alleged violations of the federal securities laws. Investors who purchased or otherwise acquired shares between January 13, 2014 and August 21, 2014, inclusive, have until July 7, 2015 to serve as lead plaintiff in the class action.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMPE:US $2.97 USD +0.06

AMPE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMPE.
View Industry Companies

Industry Analysis


Industry Average

Valuation AMPE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 608.3x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 452.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMPIO PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at